<DOC>
	<DOCNO>NCT00890786</DOCNO>
	<brief_summary>The outcome child high-grade glioma diffuse intrinsic brainstem glioma remain poor despite use multi-modal therapy surgery , radiation therapy chemotherapy .</brief_summary>
	<brief_title>A Study Bevacizumab Therapy Patients With Newly Diagnosed High-Grade Gliomas Diffuse Intrinsic Pontine Gliomas</brief_title>
	<detailed_description>Novel therapy need improve outcome child . Recent study demonstrate promising result treatment bevacizumab/irinotecan patient recurrent high grade glioma . Based promising result , tolerability irinotecan bevacizumab child recurrent CNS malignancy anecdotally study conduct Pediatric Brain Tumor Consortium , design novel study incorporate concurrent radiation therapy bevacizumab ± temozolomide follow bevacizumab , irinotecan ±temozolomide patient newly diagnose high-grade glioma diffuse intrinsic pontine glioma .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must ≥ 3 year age ≤ 30 year age time study entry . Diagnosis : Highgrade glioma ; Patients must histologically verify anaplastic astrocytoma , glioblastoma multiforme gliosarcoma.Patients primary spinal cord tumor eligible . Diffuse intrinsic pontine glioma ( DIPG ) eligible . Performance Level : Karnofsky ≥ 50 % patient &gt; 10 year age Lansky ≥ 50 patient ≤ 10 year age . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . Prior Therapy : prior anticancer therapy . Concomitant Medications : The use steroid permissible . Organ Function Requirements All patient must adequate organ function define . Adequate Bone Marrow Function Adequate Renal Function Adequate Liver Function Adequate Blood Clotting Defined As : INR , Fibrinogen , PTT &lt; Grade 2 Central nervous system function . Patients seizure may enrol seizure wellcontrolled nonenzyme inducing anticonvulsant . Informed Consent . Patients and/or parents/legal guardian must sign informed consent . Patients metastatic disease ( i.e . M+ disease , disease anywhere primary site ) . Patients evidence new intracranial hemorrhage large punctate size baseline MRI scan . Allergies : Patients history allergic reaction Chinese hamster ovary cell product , recombinant human antibody . Pregnant breast feed woman enter study . Patients childbearing childfathering potential must willing use medically acceptable form birth control , include abstinence , treat study . Infection : Patients require IV antibiotic time enrollment , currently receive treatment Clostridium difficile infection exclude . Thrombosis : Patients must previously diagnose deep venous arterial thrombosis ( include pulmonary embolism ) , must know thrombophilic condition . Serious NonHealing Wounds Surgical Procedures : Patients major surgery receive first dose bevacizumab 28 day major surgery . Patients uncontrolled systemic hypertension . Proteinuria urine protein ( albumin ) /creatinine ratio ≥1.0 .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>